Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,20420753,peak plasma concentration,Average peak plasma concentration for the six subjects with detectable 13C-phylloquinone was 2.1 nmol/l.,Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phylloquinone from kale. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420753/),[nM] / [l],2.1,11159,DB01022,Phylloquinone
,20420753,bioavailability,Modelling results demonstrated a mean (n 6) bioavailability of phylloquinone from kale to be 4.7%.,Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phylloquinone from kale. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420753/),%,4.7,11160,DB01022,Phylloquinone
,20420753,Plasma,"Plasma and tissue half-times for phylloquinone were found to be 8.8 and 215 h, respectively.",Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phylloquinone from kale. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420753/),h,8.8,11161,DB01022,Phylloquinone
,20420753,tissue half-times,"Plasma and tissue half-times for phylloquinone were found to be 8.8 and 215 h, respectively.",Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phylloquinone from kale. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420753/),h,215,11162,DB01022,Phylloquinone
,6534380,t0.5 beta,"Under simultaneous administration of phytomenadion (PHY) in daily doses of 10 mg, the elimination of phenprocoumon (PPC) was not altered (t0.5 beta 141.4 h, CUE50 20.4% of administered dose) as compared with data of previous investigations, while its anticoagulant effect was inhibited.",Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,141.4,11689,DB01022,Phylloquinone
,6534380,half-life,PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,60.6,11690,DB01022,Phylloquinone
,6534380,total body clearance (Cltot),PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],9.3,11691,DB01022,Phylloquinone
,6534380,renal clearance (Clren),PHY in doses of 10 mg was absorbed quickly and eliminated with a mean half-life of 60.6 h at a total body clearance (Cltot) of 9.3 ml/min and a renal clearance (Clren) of 1.9 ml/min.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],1.9,11692,DB01022,Phylloquinone
,6534380,half-life time,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),h,23.1,11693,DB01022,Phylloquinone
,6534380,Cltot,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],16.7,11694,DB01022,Phylloquinone
,6534380,Clren,Under the co-administration of PPC the vitamin was eliminated with a half-life time of 23.1 h (Cltot 16.7 ml/min) and the amount of excreted radioactivity was enhanced (26.3% of administered dose; Clren 4.5 ml/min) as compared with the data of PHY without co-medication.,Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6534380/),[ml] / [min],4.5,11695,DB01022,Phylloquinone
,32222983,T1/2,"T1/2 of vitamin K1 was 4.07 ± 0.41 hour, CL was 89.47 ± 3.60 mL/h, and Vd was 525.38 ± 54.45 mL in rats following PCSII.",Determination of pharmacokinetic parameters of vitamin K1 in rats after an intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222983/),h,4.07,14959,DB01022,Phylloquinone
,32222983,CL,"T1/2 of vitamin K1 was 4.07 ± 0.41 hour, CL was 89.47 ± 3.60 mL/h, and Vd was 525.38 ± 54.45 mL in rats following PCSII.",Determination of pharmacokinetic parameters of vitamin K1 in rats after an intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222983/),[ml] / [h],89.47,14960,DB01022,Phylloquinone
,32222983,Vd,"T1/2 of vitamin K1 was 4.07 ± 0.41 hour, CL was 89.47 ± 3.60 mL/h, and Vd was 525.38 ± 54.45 mL in rats following PCSII.",Determination of pharmacokinetic parameters of vitamin K1 in rats after an intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222983/),ml,525.38,14961,DB01022,Phylloquinone
,6704138,terminal (beta) half-life,Phenobarbitone pretreatment significantly (P less than 0.01) increased the plasma clearance of vitamin K1 and decreased the terminal (beta) half-life from 2.08 +/- 0.56 to 0.99 +/- 0.30 hr.,The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704138/),h,2.08,25704,DB01022,Phylloquinone
,6704138,terminal (beta) half-life,Phenobarbitone pretreatment significantly (P less than 0.01) increased the plasma clearance of vitamin K1 and decreased the terminal (beta) half-life from 2.08 +/- 0.56 to 0.99 +/- 0.30 hr.,The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704138/),h,0.99,25705,DB01022,Phylloquinone
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],659.8,27752,DB01022,Phylloquinone
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],878.1,27753,DB01022,Phylloquinone
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],1125.2,27754,DB01022,Phylloquinone
,19238731,proth,"On admission, her prothrombin time was 92.0 seconds, international normalized ratio was 5.7, and activated partial thromboplastin time was 50.2 seconds with no bleeding on clinical examination.",Bromadiolone toxicokinetics: diagnosis and treatment implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238731/),seconds,92.0,32104,DB01022,Phylloquinone
,19238731,international normalized ratio,"On admission, her prothrombin time was 92.0 seconds, international normalized ratio was 5.7, and activated partial thromboplastin time was 50.2 seconds with no bleeding on clinical examination.",Bromadiolone toxicokinetics: diagnosis and treatment implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238731/),,5.7,32105,DB01022,Phylloquinone
,19238731,activated partial thromboplastin time,"On admission, her prothrombin time was 92.0 seconds, international normalized ratio was 5.7, and activated partial thromboplastin time was 50.2 seconds with no bleeding on clinical examination.",Bromadiolone toxicokinetics: diagnosis and treatment implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238731/),seconds,50.2,32106,DB01022,Phylloquinone
,19238731,half-life,"Serial measurement of plasma bromadiolone levels confirmed the diagnosis and demonstrated that bromadiolone obeys the elimination kinetic of a two-compartment model with a rapid, fairly steep decline phase (half-life 3.5 days) followed by a slower termination phase (half-life 24 days).",Bromadiolone toxicokinetics: diagnosis and treatment implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238731/),d,3.5,32107,DB01022,Phylloquinone
,19238731,half-life,"Serial measurement of plasma bromadiolone levels confirmed the diagnosis and demonstrated that bromadiolone obeys the elimination kinetic of a two-compartment model with a rapid, fairly steep decline phase (half-life 3.5 days) followed by a slower termination phase (half-life 24 days).",Bromadiolone toxicokinetics: diagnosis and treatment implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238731/),d,24,32108,DB01022,Phylloquinone
,3383722,plasma concentration,The fetus plasma concentration rose from 8.6 micrograms/l at time 0 to 0 to 44.3 micrograms/l at 8 h.,Vitamin K1 diffusion across the placental barrier in the gravid female rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383722/),[μg] / [l],8.6,33849,DB01022,Phylloquinone
,3383722,plasma concentration,The fetus plasma concentration rose from 8.6 micrograms/l at time 0 to 0 to 44.3 micrograms/l at 8 h.,Vitamin K1 diffusion across the placental barrier in the gravid female rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383722/),[μg] / [l],44.3,33850,DB01022,Phylloquinone
,6661354,terminal half-life,"For each compound administered alone the plasma concentration-time profile was adequately fitted by a biexponential equation, with an average terminal half-life of 2.0 and 1.15 h for the administered vitamin K and its 2,3-epoxide respectively.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,2.0,42263,DB01022,Phylloquinone
,6661354,terminal half-life,"For each compound administered alone the plasma concentration-time profile was adequately fitted by a biexponential equation, with an average terminal half-life of 2.0 and 1.15 h for the administered vitamin K and its 2,3-epoxide respectively.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,1.15,42264,DB01022,Phylloquinone
,6661354,half-life,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,1.5,42265,DB01022,Phylloquinone
,6661354,area under the plasma concentration-time profile,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),[h·mg] / [l],1.76,42266,DB01022,Phylloquinone
,6661354,half-life,"Following pretreatment with phenprocoumon and after intravenous administration of vitamin K1, both the average half-life and area under the plasma concentration-time profile of vitamin K1 were marginally reduced to 1.5 h and 1.76 mg l-1 h respectively, while the plasma concentration of vitamin K1-2,3-epoxide was readily measurable and its half-life markedly prolonged to 14.7 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,14.7,42267,DB01022,Phylloquinone
,6661354,half-life,"Following pretreatment with phenprocoumon and after oral administration of vitamin K1-2,3-epoxide, no vitamin K1 was detectable in plasma and the half-life of the epoxide was 13.8 h.","Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661354/),h,13.8,42268,DB01022,Phylloquinone
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,47.8,45288,DB01022,Phylloquinone
,2938614,plasma half-life,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),h,57.8,45289,DB01022,Phylloquinone
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],2.3,45290,DB01022,Phylloquinone
,2938614,plasma clearance,Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02).,Stereoselective interaction between the R enantiomer of warfarin and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938614/),[ml] / [h·kg],1.7,45291,DB01022,Phylloquinone
,18952509,C(max),The C(max) was 210.1+/-86.7 ng/ml while the elimination half-life (t(1/2)) was 8.8+/-1.7h and time to the C(max) was 5.5+/-0.8h after administration of soft capsule containing 10mg VK-1.,HPLC-APCI-MS for the determination of vitamin K(1) in human plasma: method and clinical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18952509/),[ng] / [ml],210.1,46007,DB01022,Phylloquinone
,18952509,elimination half-life (t(1/2)),The C(max) was 210.1+/-86.7 ng/ml while the elimination half-life (t(1/2)) was 8.8+/-1.7h and time to the C(max) was 5.5+/-0.8h after administration of soft capsule containing 10mg VK-1.,HPLC-APCI-MS for the determination of vitamin K(1) in human plasma: method and clinical application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18952509/),h,8.8,46008,DB01022,Phylloquinone
,18952509,time to the C(max),The C(max) was 210.1+/-86.7 ng/ml while the elimination half-life (t(1/2)) was 8.8+/-1.7h and time to the C(max) was 5.5+/-0.8h after administration of soft capsule containing 10mg VK-1.,HPLC-APCI-MS for the determination of vitamin K(1) in human plasma: method and clinical application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18952509/),h,5.5,46009,DB01022,Phylloquinone
,8471414,systemic clearance,The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],114,50033,DB01022,Phylloquinone
,8471414,systemic clearance,The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],112,50034,DB01022,Phylloquinone
,8471414,AUC,The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[μg] / [ml],6.5,50035,DB01022,Phylloquinone
,8471414,AUC,The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects.,High clearance of (S)-warfarin in a warfarin-resistant subject. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[min·μg] / [ml],139,50036,DB01022,Phylloquinone
,8471414,oral clearance,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],14.5,50037,DB01022,Phylloquinone
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],2.6,50038,DB01022,Phylloquinone
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],4.3,50039,DB01022,Phylloquinone
,8471414,clearance ratio,"In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),,1.2,50040,DB01022,Phylloquinone
,8471414,clearance,"In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),[ml] / [min],16.2,50041,DB01022,Phylloquinone
,8471414,clearance ratio,"In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).",High clearance of (S)-warfarin in a warfarin-resistant subject. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471414/),,2.7,50042,DB01022,Phylloquinone
,1548622,elimination half-life,A mean BDF elimination half-life of 6 +/- 4 days was observed.,Coagulopathic effects and therapy of brodifacoum toxicosis in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1548622/),d,6,51827,DB01022,Phylloquinone
,2802168,accumulation time,A carbon paste electrode containing Nujol - Ultra Carbon Ultra Superior Purity graphite (25 + 75 m/m) gave the highest sensitivity with adsorptive stripping voltammetry; the optimum accumulation time was 15 min at an open circuit.,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),min,15,53457,DB01022,Phylloquinone
,2802168,recovery,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),%,91,53458,DB01022,Phylloquinone
,2802168,detection limits,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),[ng] / [ml],180,53459,DB01022,Phylloquinone
,2802168,detection limits,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),[ng] / [ml],450,53460,DB01022,Phylloquinone
,2568466,Maximum plasma concentrations,"Maximum plasma concentrations of vitamin K1 (450 ng mL-1, range 133-824 ng mL-1) were recorded at 3.3 h (range 3-5 h), and were significantly (P less than 0.05) greater than those seen after administration of an existing polyethoxylated castor oil preparation (PE-K; Konakion), which were 260 ng mL-1, range 198-390 ng mL-1 (tmax 0.8 h, range 0.4-1.2 h).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),[ng] / [ml],450,75185,DB01022,Phylloquinone
,2568466,Maximum plasma concentrations,"Maximum plasma concentrations of vitamin K1 (450 ng mL-1, range 133-824 ng mL-1) were recorded at 3.3 h (range 3-5 h), and were significantly (P less than 0.05) greater than those seen after administration of an existing polyethoxylated castor oil preparation (PE-K; Konakion), which were 260 ng mL-1, range 198-390 ng mL-1 (tmax 0.8 h, range 0.4-1.2 h).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),[ng] / [ml],260,75186,DB01022,Phylloquinone
,2568466,tmax,"Maximum plasma concentrations of vitamin K1 (450 ng mL-1, range 133-824 ng mL-1) were recorded at 3.3 h (range 3-5 h), and were significantly (P less than 0.05) greater than those seen after administration of an existing polyethoxylated castor oil preparation (PE-K; Konakion), which were 260 ng mL-1, range 198-390 ng mL-1 (tmax 0.8 h, range 0.4-1.2 h).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),h,0.8,75187,DB01022,Phylloquinone
,2568466,AUC,"AUC after MM-K (4.6 micrograms mL-1 h-1, range 2.1-6.3 micrograms ML-1 h-1) was also significantly (P less than 0.05) greater than after PE-K (1.6 micrograms mL-1 h-1, range 1.0-2.1 micrograms ML-1 h-1).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),[μg] / [h·ml],4.6,75188,DB01022,Phylloquinone
,2568466,AUC,"AUC after MM-K (4.6 micrograms mL-1 h-1, range 2.1-6.3 micrograms ML-1 h-1) was also significantly (P less than 0.05) greater than after PE-K (1.6 micrograms mL-1 h-1, range 1.0-2.1 micrograms ML-1 h-1).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),[μg] / [h·ml],1.6,75189,DB01022,Phylloquinone
,2568466,bioavailability,"However, the bioavailability of vitamin K1 after administration of MM-K was poor (9.4%), and there was considerable intra-individual variability between the concentrations of vitamin K1 recorded in the plasma samples.","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),%,9.4,75190,DB01022,Phylloquinone
,2568466,tmax,"The maximum was seen later (tmax 12 h) than after PE-K (PCA 82%, range 47-125%; tmax 5 h).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),h,12,75191,DB01022,Phylloquinone
,2568466,tmax,"The maximum was seen later (tmax 12 h) than after PE-K (PCA 82%, range 47-125%; tmax 5 h).","The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568466/),h,5,75192,DB01022,Phylloquinone
,6487353,terminal half-life,"Plasma concentrations of vitamin K1 fell steeply during the 12 hr following administration of a pharmacological dose, and then declined with a terminal half-life of 18.9 +/- 9.0 hr.",A study of factors which determine the pharmacological response to vitamin K in coumarin anticoagulated rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487353/),h,18.9,90293,DB01022,Phylloquinone
≥,28107923,recovery,"A simple and cost effective procedure was implemented with the combination of protein precipitation and liquid extraction, to isolate the targets from plasma sample, while achieving an insignificant matrix effects and high recovery (≥88.2%).","A sensitive and rapid UFLC-APCI-MS/MS bioanalytical method for quantification of endogenous and exogenous Vitamin K1 isomers in human plasma: Development, validation and first application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28107923/),%,88.2,98725,DB01022,Phylloquinone
,31736367,Initial plasma levels,"Initial plasma levels were 581 ± 87, 11.0 ± 1.9, and 14.9 ± 5.9 ng/mL for BDF, DiF, and BDL, respectively (mean ± SE).",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),[ng] / [ml],581,114271,DB01022,Phylloquinone
,31736367,Initial plasma levels,"Initial plasma levels were 581 ± 87, 11.0 ± 1.9, and 14.9 ± 5.9 ng/mL for BDF, DiF, and BDL, respectively (mean ± SE).",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),[ng] / [ml],11.0,114272,DB01022,Phylloquinone
,31736367,Initial plasma levels,"Initial plasma levels were 581 ± 87, 11.0 ± 1.9, and 14.9 ± 5.9 ng/mL for BDF, DiF, and BDL, respectively (mean ± SE).",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),[ng] / [ml],14.9,114273,DB01022,Phylloquinone
,31736367,Plasma half-lives,"Plasma half-lives for BDF, DiF, and BDL were 7.5 ± 1.3, 7.2 ± 1.9, and 1.8 ± 0.3 days, respectively.",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),d,7.5,114274,DB01022,Phylloquinone
,31736367,Plasma half-lives,"Plasma half-lives for BDF, DiF, and BDL were 7.5 ± 1.3, 7.2 ± 1.9, and 1.8 ± 0.3 days, respectively.",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),d,7.2,114275,DB01022,Phylloquinone
,31736367,Plasma half-lives,"Plasma half-lives for BDF, DiF, and BDL were 7.5 ± 1.3, 7.2 ± 1.9, and 1.8 ± 0.3 days, respectively.",Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),d,1.8,114276,DB01022,Phylloquinone
,31736367,half-life,The half-life for trans-BDF enantiomers (5.7 ± 0.8 days) was shorter than for cis-enantiomers (7.6 ± 1.9 days).,Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),d,5.7,114277,DB01022,Phylloquinone
,31736367,half-life,The half-life for trans-BDF enantiomers (5.7 ± 0.8 days) was shorter than for cis-enantiomers (7.6 ± 1.9 days).,Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736367/),d,7.6,114278,DB01022,Phylloquinone
,28346840,bioavailability,"Owing to its limited aqueous solubility, Phytomenadione (vitamin K) undergoes a low bioavailability (50%) with a large inter-individual variability after oral administration.",Fabrication and evaluation of Phytomenadione as a nanostructure lipid carrier for enhancement of bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346840/),%,50,124201,DB01022,Phylloquinone
,28346840,relative bioavailability,"This formula was also chemically and physically stable, and it recorded a relative bioavailability of 645.5% in rabbits compared to the commercial conventional tablet.",Fabrication and evaluation of Phytomenadione as a nanostructure lipid carrier for enhancement of bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28346840/),%,645.5,124202,DB01022,Phylloquinone
,25308231,VK1,"Additionally, the increases in VK1 concentrations were similar (tablets, 3.2 μg L(-1) ; solution, 3.4 μg L(-1) ; P = 0.99) after 24 h.",Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308231/),[μg] / [l],3.2,126411,DB01022,Phylloquinone
,25308231,VK1,"Additionally, the increases in VK1 concentrations were similar (tablets, 3.2 μg L(-1) ; solution, 3.4 μg L(-1) ; P = 0.99) after 24 h.",Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25308231/),[μg] / [l],3.4,126412,DB01022,Phylloquinone
,11503010,clearance,"Warfarin doses decreased with age as follows: 7.7 +/- 3.7 versus 4.9 +/- 2.9 mg/d at < 50 years and >66 years (P < .001), mainly as a result of decreased plasma warfarin clearance (2.8 +/- 1.4 mL/min versus 1.9 +/- 0.8 mL/min; P < .001).",Interindividual variability in sensitivity to warfarin--Nature or nurture? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503010/),[ml] / [min],2.8,128613,DB01022,Phylloquinone
,11503010,clearance,"Warfarin doses decreased with age as follows: 7.7 +/- 3.7 versus 4.9 +/- 2.9 mg/d at < 50 years and >66 years (P < .001), mainly as a result of decreased plasma warfarin clearance (2.8 +/- 1.4 mL/min versus 1.9 +/- 0.8 mL/min; P < .001).",Interindividual variability in sensitivity to warfarin--Nature or nurture? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11503010/),[ml] / [min],1.9,128614,DB01022,Phylloquinone
,4042792,plasma half-life,"In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min).",Pharmacokinetics of vitamin K1 in low-birth-weight neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042792/),min,18 and 52,130183,DB01022,Phylloquinone
,4042792,plasma half-life,"In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min).",Pharmacokinetics of vitamin K1 in low-birth-weight neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042792/),min,23,130184,DB01022,Phylloquinone
,4042792,half-life,"In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min).",Pharmacokinetics of vitamin K1 in low-birth-weight neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042792/),min,67 and 179,130185,DB01022,Phylloquinone
,4042792,half-life,"In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min).",Pharmacokinetics of vitamin K1 in low-birth-weight neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042792/),min,109,130186,DB01022,Phylloquinone
,8250654,initial half-life,"Brodifacoum was eliminated according to a two-compartment model, with an initial half-life of 0.75 days and a terminal half-life of 24.2 days.",Case management and plasma half-life in a case of brodifacoum poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250654/),d,0.75,132788,DB01022,Phylloquinone
,8250654,terminal half-life,"Brodifacoum was eliminated according to a two-compartment model, with an initial half-life of 0.75 days and a terminal half-life of 24.2 days.",Case management and plasma half-life in a case of brodifacoum poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250654/),d,24.2,132789,DB01022,Phylloquinone
,23373428,limit of quantification (LOQ),The limit of quantification (LOQ) was 20 ng/mL for vitamin D3 and 40 ng/mL for K1.,A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ng] / [ml],20,136850,DB01022,Phylloquinone
,23373428,limit of quantification (LOQ),The limit of quantification (LOQ) was 20 ng/mL for vitamin D3 and 40 ng/mL for K1.,A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ng] / [ml],40,136851,DB01022,Phylloquinone
,23373428,AUC0-∞,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[h·ng] / [ml],11323,136852,DB01022,Phylloquinone
,23373428,Vd,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [kg],218,136853,DB01022,Phylloquinone
,23373428,CL,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [h·kg],8.9,136854,DB01022,Phylloquinone
,23373428,t1/2,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),h,16.8,136855,DB01022,Phylloquinone
,23373428,AUC0-∞,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[h·ng] / [ml],2495,136856,DB01022,Phylloquinone
,23373428,Vd,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [kg],60,136857,DB01022,Phylloquinone
,23373428,CL,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),[ml] / [h·kg],40.5,136858,DB01022,Phylloquinone
,23373428,t1/2,"The pharmacokinetic parameters of vitamin D3 following intravenous administration were: AUC0-∞ = 11323 ± 1081 h × ng/mL, Vd = 218 ± 80 mL/kg, CL = 8.9 ± 0.8 mL/h/kg, t1/2 = 16.8 ± 5 h; and of vitamin K1: AUC0-∞ = 2495 ± 297 h × ng/mL, Vd = 60 ±24 mL/kg, CL = 40.5 ± 5.1 mL/h/kg, t1/2 = 1.1 ±0.5 h.",A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373428/),h,1.1,136859,DB01022,Phylloquinone
below,8799516,systemic availability,Pharmacokinetic analysis of plasma phylloquinone(vitamin K1) concentration vs time profiles revealed that in one-fifth of the subjects systemic availability of intramuscular phylloquinone (vitamin K1) was below 65%.,Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799516/),%,65,168327,DB01022,Phylloquinone
,17671443,half-times,The disposal kinetics of the intravenous dose of vitamin K(1) were resolved into two exponentials with half-times of 0.22 (+/-0.14) and 2.66 (+/-1.69) h.,A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17671443/),h,0.22,172359,DB01022,Phylloquinone
,17671443,half-times,The disposal kinetics of the intravenous dose of vitamin K(1) were resolved into two exponentials with half-times of 0.22 (+/-0.14) and 2.66 (+/-1.69) h.,A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17671443/),h,2.66,172360,DB01022,Phylloquinone
,17671443,Absorption,"Absorption of oral, deuterated vitamin K(1) was 13 (+/-9)%.",A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17671443/),%,13,172361,DB01022,Phylloquinone
,9483171,plasma half-life,The plasma half-life of phenprocoumon was approximately 350 h (normal 120-150 h).,Vitamin K metabolism in a patient resistant to vitamin K antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483171/),h,350,209422,DB01022,Phylloquinone
,4091996,terminal half-life,"The pharmacokinetics of vitamin K1 in patients were similar to those reported previously in healthy volunteers, terminal half-life 1.7 h.",Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),h,1.7,229024,DB01022,Phylloquinone
,4091996,plasma concentrations,Steady state warfarin plasma concentrations ranged from 0.5 to 1.4 micrograms ml-1.,Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),,0.5 to 1.4,229025,DB01022,Phylloquinone
,4091996,Pro,Prothrombin complex activity ranged from 15 to 28.5%.,Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),%,15 to 28.5,229026,DB01022,Phylloquinone
,4091996,CPmax,"All the patients on warfarin had measurable levels (CPmax 0.3-1.2 micrograms ml-1) of vitamin K1 2, 3-epoxide.",Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091996/),[μg] / [ml],0.3-1.2,229027,DB01022,Phylloquinone
,10973675,measured,The measured plasma concentration after intravenous administration of vitamin K(1) was 191.3+/-102.6 ng vitamin K in the first sample /mL in the first sample and 98.7+/-75.2 ng vitamin K(1)/mL in the second samples.,Plasma concentrations after intravenous administration of phylloquinone (vitamin K(1)) in preterm and sick neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10973675/),ng,191.3,252549,DB01022,Phylloquinone
,10973675,measured,The measured plasma concentration after intravenous administration of vitamin K(1) was 191.3+/-102.6 ng vitamin K in the first sample /mL in the first sample and 98.7+/-75.2 ng vitamin K(1)/mL in the second samples.,Plasma concentrations after intravenous administration of phylloquinone (vitamin K(1)) in preterm and sick neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10973675/),[k(1·ng·vitamin] / [ml],98.7,252550,DB01022,Phylloquinone
,10973675,plasma concentration,The measured plasma concentration after intravenous administration of vitamin K(1) was 191.3+/-102.6 ng vitamin K in the first sample /mL in the first sample and 98.7+/-75.2 ng vitamin K(1)/mL in the second samples.,Plasma concentrations after intravenous administration of phylloquinone (vitamin K(1)) in preterm and sick neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10973675/),ng,191.3,252551,DB01022,Phylloquinone
,10973675,plasma concentration,The measured plasma concentration after intravenous administration of vitamin K(1) was 191.3+/-102.6 ng vitamin K in the first sample /mL in the first sample and 98.7+/-75.2 ng vitamin K(1)/mL in the second samples.,Plasma concentrations after intravenous administration of phylloquinone (vitamin K(1)) in preterm and sick neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10973675/),[k(1·ng·vitamin] / [ml],98.7,252552,DB01022,Phylloquinone
,19941044,clearance,The presence of a single *2 or *3 CYP2C9 allele reduced mean [SE (standard error)] S-warfarin clearance by 35% from 0.276 (0.04) to 0.180 (0.11) l/h.,Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[l] / [h],0.276,257160,DB01022,Phylloquinone
,19941044,clearance,The presence of a single *2 or *3 CYP2C9 allele reduced mean [SE (standard error)] S-warfarin clearance by 35% from 0.276 (0.04) to 0.180 (0.11) l/h.,Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[l] / [h],0.180,257161,DB01022,Phylloquinone
,19941044,"C (50,S)","Subjects with VKORC1 haplotype groups of H7H7 had increased mean (SE) C (50,S) (concentration of S-warfarin required to achieve 50% of maximum effect) of 479 (7.3) compared to 206 (6.7) ng/ml in subjects with the H1H1 groups.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],479,257162,DB01022,Phylloquinone
,19941044,"C (50,S)","Subjects with VKORC1 haplotype groups of H7H7 had increased mean (SE) C (50,S) (concentration of S-warfarin required to achieve 50% of maximum effect) of 479 (7.3) compared to 206 (6.7) ng/ml in subjects with the H1H1 groups.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],206,257163,DB01022,Phylloquinone
,19941044,"C (50,S)","For subjects with the H1H7 haplotype, mean (SE) C (50,S) increased 1.4 times to 288 (1.3) ng/ml compared to subjects with H1H1 haplotypes.",Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19941044/),[ng] / [ml],288,257164,DB01022,Phylloquinone
